• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis.

作者信息

Isfort Susanne, Gambacorti-Passerini Carlo, Brümmendorf Tim H, Smith B Douglas, Purcell Simon, Strecker Maja, Zhao Huadong, Kuttschreuter Luke, Apperley Jane

机构信息

Department of Hematology, Hemostasis, Oncology and Stem Cell Translation, Comprehensive Cancer Center Hannover (Claudia von Schilling-Center), Medical School Hannover (MHH), Hannover, Germany; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany.

University of Milano-Bicocca, Monza, Italy.

出版信息

Leuk Res. 2024 Dec;147:107609. doi: 10.1016/j.leukres.2024.107609. Epub 2024 Oct 24.

DOI:10.1016/j.leukres.2024.107609
PMID:39471734
Abstract
摘要

相似文献

1
The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis.体重指数对慢性白血病患者使用博舒替尼安全性的影响：一项事后汇总数据分析。
Leuk Res. 2024 Dec;147:107609. doi: 10.1016/j.leukres.2024.107609. Epub 2024 Oct 24.
2
Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.博舒替尼：一种用于治疗慢性粒细胞白血病的SRC-ABL酪氨酸激酶抑制剂。
Pharmgenomics Pers Med. 2013 Aug 5;6:57-62. doi: 10.2147/PGPM.S32145.
3
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.泊马度胺在慢性髓性白血病日本患者与非日本患者中的安全性特征：汇总分析。
Int J Hematol. 2022 Jun;115(6):838-851. doi: 10.1007/s12185-022-03314-y. Epub 2022 Mar 2.
4
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.两种酪氨酸激酶抑制剂治疗失败的慢性期慢性髓性白血病患者中，ponatinib 与 bosutinib 的获益与风险：匹配调整间接比较。
Curr Med Res Opin. 2019 Mar;35(3):479-487. doi: 10.1080/03007995.2018.1510225. Epub 2018 Aug 24.
5
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.在先前接受伊马替尼和/或达沙替尼和/或尼洛替尼治疗的患者中，博舒替尼的疗效和安全性：来自 4 期 BYOND 研究的亚组分析。
Leuk Res. 2024 Apr;139:107481. doi: 10.1016/j.leukres.2024.107481. Epub 2024 Mar 11.
6
Bosutinib for Chronic Myeloid Leukemia.博舒替尼用于治疗慢性髓性白血病。
Rare Cancers Ther. 2015;3(1):35-46. doi: 10.1007/s40487-015-0010-y. Epub 2015 Aug 26.
7
Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.博舒替尼治疗慢性期慢性髓性白血病患者的药代动力学-药效学关系。
Cancer Chemother Pharmacol. 2013 Jan;71(1):209-18. doi: 10.1007/s00280-012-1998-4. Epub 2012 Oct 16.
8
Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia.博舒替尼在一名儿童慢性髓性白血病患者中的药代动力学、疗效及安全性
J Pediatr Pharmacol Ther. 2020;25(8):742-745. doi: 10.5863/1551-6776-25.8.742. Epub 2020 Nov 13.
9
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.博舒替尼治疗费城染色体阳性（Ph+）慢性髓性白血病患者的概述
Ther Adv Hematol. 2014 Feb;5(1):13-7. doi: 10.1177/2040620713510481.
10
Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.博舒替尼：一种用于治疗慢性髓性白血病的第三代酪氨酸激酶抑制剂。
Expert Rev Anticancer Ther. 2014 Jul;14(7):765-70. doi: 10.1586/14737140.2014.924400. Epub 2014 May 30.

引用本文的文献

1
A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative review.深入探讨慢性髓性白血病中肥胖的手术和药理学考量：一项叙述性综述。
Front Oncol. 2025 Jul 4;15:1616883. doi: 10.3389/fonc.2025.1616883. eCollection 2025.